Sangamo BioSciences Inc. (NASDAQ:SGMO) shares rose 1.3% on Friday . The stock traded as high as $5.74 and last traded at $5.66, with a volume of 273,702 shares traded. The stock had previously closed at $5.59.

SGMO has been the subject of several research analyst reports. Jefferies Group reissued a “buy” rating and issued a $14.00 price objective on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Zacks Investment Research lowered Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Wells Fargo & Co. initiated coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They issued a “buy” rating for the company. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Sangamo BioSciences in a research report on Friday, May 6th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.75.

The company’s 50 day moving average is $6.19 and its 200 day moving average is $6.27. The stock’s market capitalization is $403.21 million.

Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. During the same quarter in the previous year, the company earned ($0.08) earnings per share. The business had revenue of $3.94 million for the quarter, compared to analysts’ expectations of $5.49 million. The business’s quarterly revenue was down 70.8% on a year-over-year basis. Analysts anticipate that Sangamo BioSciences Inc. will post ($0.98) earnings per share for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. California State Teachers Retirement System raised its stake in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,941 shares of the biopharmaceutical company’s stock after buying an additional 2,257 shares during the period. California State Teachers Retirement System owned approximately 0.18% of Sangamo BioSciences worth $1,177,000 as of its most recent SEC filing.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.